Creating a Clinicobiological Database for Patients With Metastatic Digestive Adenocarcinoma Receiving 1st or 2nd Line Chemotherapy or Targeted Therapy

What this Trial Is About

Digestive cancers, including colorectal cancer, are a major health concern worldwide, accounting for 30% of all cancers. This research aims to create a collection of blood samples from patients with metastatic digestive adenocarcinoma who are receiving first or second line treatments. The goal is to study blood biomarkers that could help tailor treatments by predicting and monitoring response in a minimally invasive way. Patients in the study will have blood samples collected before starting treatment and then approximately every two months during treatment until it ends. Alongside this biological collection, standardized clinical data will be recorded in a database. This approach focuses on blood rather than tumor tissue, allowing repeated sampling to better understand tumor dynamics and treatment effects. Participants will be involved throughout their treatment period with regular blood draws and clinical data collection. Researchers will measure clinical and biological risk factors related to metastatic digestive cancer over a study period of up to 54 months. This ongoing monitoring aims to support research projects that improve personalized patient management strategies. The study is sponsored by the Institut du Cancer de Montpellier - Val dAurelle.

A Clinicobiological Database in Metastatic Digestive Cancers